Marshall Wace
KYTX icon

Marshall Wace’s Kyverna Therapeutics KYTX Stock Holding History

Marshall Wace’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-605,512
Closed -$5.23M – 3833
2026
Q1 		$5.23M Buy
605,512
+469,912
+347% +$3.92M 0.01% 1281
2025
Q4 		$1.27M Buy
+135,600
New +$1.01M ﹤0.01% 1810
2025
Q3 		– Sell
-62,057
Closed -$191K – 3500
2025
Q2 		$191K Buy
62,057
+37,496
+153% +$92.7K ﹤0.01% 2465
2025
Q1 		$47.4K Buy
24,561
+9,320
+61% +$27.5K ﹤0.01% 2537
2024
Q4 		$57K Sell
15,241
-16,982
-53% -$81.4K ﹤0.01% 2483
2024
Q3 		$158K Buy
32,223
+21,823
+210% +$168K ﹤0.01% 2324
2024
Q2 		$78K Sell
10,400
-145,355
-93% -$2.22M ﹤0.01% 2412
2024
Q1 		$3.87M Buy
+155,755
New +$4.35M 0.01% 1102

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Marshall Wace's KYTX Position: Q2 2026 in Review

Marshall Wace sold out of Kyverna Therapeutics (KYTX) in Q2 2026, closing a stake of 605,512 shares — an estimated $5.23M sold.

Marshall Wace first reported a position in KYTX in Q1 2024 and held it in 8 quarters. The position peaked at $5.23M in Q1 2026. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Marshall Wace reported no remaining Kyverna Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Marshall Wace sold 605,512 Kyverna Therapeutics shares in Q2 2026, an estimated $5.23M.
  • Marshall Wace first reported a position in Kyverna Therapeutics in Q1 2024 and held it in 8 quarters.
  • Marshall Wace's Kyverna Therapeutics position peaked at $5.23M in Q1 2026.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.